A skin-transparent essence that balances pigmentation and repairs cells

Abstract

This invention relates to the field of skincare technology and discloses a skin-penetrating essence that balances pigmentation and repairs cells. The essence comprises the following components by weight percentage: aqueous carrier 45-80%; ethanol 2-8%; propylene glycol 3-10%; tranexamic acid 1-5%; resveratrol 0.5-3%; salicylic acid 0.2-2%; arbutin 1-4%; dimethyl sulfone 0.5-4%; butylene glycol 2-6%; azelaic acid 0.5-3%; ginseng extract 0.1-2%; angelica extract 0.1-2%; oat extract 0.5-3%; Stephania tetrandra extract 0.2-1.5%; Centella asiatica extract 0.5-3%; aloe vera extract 0.5-2.5%; golden chamomile extract 0.2-2%; caramel color 0.01-0.1%; 1,2-hexanediol 0.5-2%; p-hydroxyacetophenone 0.1-1%. The mass ratio of tranexamic acid, arbutin, and azelaic acid is (1-3):(1-2):(0.5-1.5). Brightening and fading effect: The tranexamic acid, arbutin, azelaic acid, and salicylic acid in the formula work synergistically to help inhibit melanin production, accelerate keratin metabolism, improve uneven skin tone and dullness, and make the skin more radiant and even-toned.

Description

Technical Field

[0001] This invention relates to the field of skincare technology, specifically to a transdermal serum that balances pigmentation and repairs cells. Background Technology

[0002] Pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation (PIH), freckles, and photoaging pigmentation, are common problems in dermatology and cosmetic skincare. Their core pathological mechanisms involve excessive activation of melanocytes, abnormally elevated tyrosinase activity, abnormal transport of melanosomes to keratinocytes, and damage to the basement membrane at the epidermal-dermal junction. Furthermore, recent studies have shown that chronic inflammation, mitochondrial oxidative stress, deposition of advanced glycation end products (AGEs), and autophagy dysfunction also participate in and exacerbate the pathological changes in pigment cells. Therefore, an ideal treatment or improvement strategy should address both "inhibition of pigment synthesis" and "repair of cellular function" simultaneously.

[0003] Currently, there are various serum products on the market with whitening and spot-fading effects. Based on the mechanism of action of their active ingredients, they can be mainly divided into the following categories: The first category is tyrosinase inhibitors, such as arbutin, kojic acid, and azelaic acid, which reduce melanin production by competitively or non-competitively inhibiting the activity of tyrosinase; the second category is melanin reducing agents, such as vitamin C and its derivatives, which can reduce dopaquinone to dopa, thereby blocking the oxidation chain reaction of melanin; the third category is keratolytic agents, such as glycolic acid (glycolic acid, lactic acid) and salicylic acid, which achieve a rapid spot-fading effect by promoting the shedding of keratinocytes containing pigment granules; the fourth category is anti-inflammatory and anti-melanin signaling agents, such as tranexamic acid, which reduces inflammation-induced melanocyte activation by inhibiting the plasmin-plasminogen system and prostaglandin E2.

[0004] However, existing whitening and spot-fading serums still have the following shortcomings:

[0005] First, the limitations of a single mechanism of action. Most existing products rely on only one or two whitening ingredients, primarily targeting tyrosinase activity, failing to simultaneously address oxidative stress, mitochondrial damage, autophagy disorders, and basement membrane repair in pigment cells. Simply inhibiting melanin synthesis while neglecting the cell's own functional repair often leads to pigmentation rebound or short-lived effects after discontinuation.

[0006] Second, the transdermal absorption efficiency of active ingredients is low. The stratum corneum barrier is the main obstacle preventing water-soluble or poorly soluble whitening ingredients (such as tranexamic acid, azelaic acid, and resveratrol) from penetrating the deep layers of the epidermis. Although existing products often add ethanol as a penetration enhancer, single-alcohol systems are prone to causing skin irritation and barrier damage, and lack an overall penetration-enhancing effect on various active ingredients with different solubility properties, resulting in the actual drug concentration reaching the target site being far lower than the effective concentration.

[0007] Third, it is difficult to balance formulation stability and irritation. For example, salicylic acid and azelaic acid have excellent exfoliating and anti-inflammatory effects, but both have poor solubility in conventional formulations and are prone to causing skin irritation such as stinging and erythema. Resveratrol and arbutin are both photosensitive ingredients that are easily oxidized and discolored during storage and use, thus losing their effectiveness. Current technologies lack a comprehensive solution that simultaneously addresses the irritation of salicylic acid / azelaic acid, the stability of photosensitive ingredients, and the reduction of skin irritation.

[0008] Fourth, there is a lack of targeted repair of melanocytes. Although existing products sometimes contain plant extracts such as ginseng, angelica, and centella asiatica, they are mostly simple compound formulations and lack a targeted delivery system for damaged melanocytes. Furthermore, the proportions and synergistic effects between the extracts lack systematic optimization, making it difficult to truly achieve targeted repair of mitochondrial membrane potential, autophagy levels, and dendritic structures in melanocytes.

[0009] Fifth, there is a lack of synergistic design between anti-inflammatory and pigmentation-inhibiting agents. Inflammation is both a cause and a consequence of pigmentation. Few existing products combine TRPV1 channel inhibitors (such as Stephania tetrandra extract) with anti-inflammatory and repair-promoting agents (such as Centella asiatica extract) in a specific ratio to simultaneously inhibit neurogenic and immunogenic inflammation, thereby blocking the vicious cycle of "inflammation-pigmentation-further inflammation".

[0010] In conclusion, developing a transdermal serum that can simultaneously achieve efficient transdermal absorption, multi-target inhibition of pigment synthesis, repair of damaged melanocyte function, reduced irritation, and good photostability remains a pressing technical challenge in this field. Summary of the Invention

[0011] (a) Technical problems to be solved

[0012] To address the shortcomings of existing technologies, this invention provides a skin-penetrating essence that balances pigmentation and repairs cells, thus solving the problems mentioned in the background section.

[0013] (II) Technical Solution

[0014] To achieve the above objectives, the present invention provides the following technical solution: a skin-penetrating essence that balances pigmentation and repairs cells, wherein the skin-penetrating essence is composed of the following components by weight percentage:

[0015] Aqueous carrier 45-75%;

[0016] Ethanol 2-8%;

[0017] Propylene glycol 3-10%;

[0018] Tranexamic acid 1-5%;

[0019] Resveratrol 0.5-3%;

[0020] Salicylic acid 0.2-2%;

[0021] Arbutin 1-4%;

[0022] Dimethyl sulfone 0.5-4%;

[0023] Butanediol 2-6%;

[0024] Azelaic acid 0.5-3%;

[0025] Ginseng extract 0.1-2%;

[0026] Angelica sinensis extract 0.1-2%;

[0027] Oat extract 0.5-3%;

[0028] Stephania tetrandra extract 0.2-1.5%;

[0029] Centella asiatica extract 0.5-3%;

[0030] Curacao aloe vera extract 0.5-2.5%;

[0031] Golden chamomile extract 0.2-2%;

[0032] Caramel color 0.01-0.1%;

[0033] 1,2-Hexanediol 0.5-2%;

[0034] p-Hydroxyacetophenone 0.1-1%.

[0035] Preferably, the mass ratio of tranexamic acid, arbutin and azelaic acid is (1-3):(1-2):(0.5-1.5), and the mass ratio of resveratrol to salicylic acid is (1-2):(0.5-1).

[0036] The azelaic acid and the dimethyl sulfone form a eutectic complex in a molar ratio of 1:0.8-1.2. The eutectic complex is prepared by mixing azelaic acid and dimethyl sulfone, heating and stirring at 40-50°C until completely melted, then cooling to room temperature and grinding into powder.

[0037] Preferably, the mass ratio of the Stephania tetrandra extract to the Centella asiatica extract is 1:(1.5-3).

[0038] The content of fangchi alkaloid in the powdered fangchi extract is 5-15 wt%, and the content of asiaticoside in the centella asiatica extract is 10-25 wt%.

[0039] Preferably, the transdermal essence further comprises liposomes, which are composed of hydrogenated lecithin, cholesterol, resveratrol, ginseng extract, and angelica extract, and the mass ratio of the four is (5-10):(1-2):(1-1.5):(0.5-1).

[0040] The liposomes have a particle size of 80-150 nm, and the resveratrol, ginseng extract, and angelica extract are encapsulated together in the aqueous phase of the liposomes.

[0041] Preferably, the oat extract is an enzymatically hydrolyzed extract with a β-glucan content ≥20wt%, and the aloe vera extract is an extract with an acetylated mannan content ≥15wt%.

[0042] The mass ratio of 1,2-hexanediol to p-hydroxyacetophenone is (1-2):(0.5-1).

[0043] The caramel color has a color factor of 0.1-0.5 and a transmittance of ≤10% in the wavelength range of 290-320nm.

[0044] Preferably, the pH value of the transdermal essence is 4.0-5.5, and the mass ratio of ethanol, propylene glycol and butylene glycol is (1-2):(2-4):(1-3).

[0045] At this mass ratio and pH value, the proportion of salicylic acid existing in an undissociated molecular state is 65-85%.

[0046] Preferably, the mass ratio of dimethyl sulfone, tranexamic acid and resveratrol is (1-2):(2-4):(1-2).

[0047] The ginseng extract contains 0.5-2 wt% ginsenoside Rg1, and the angelica extract contains 0.3-1.5 wt% ferulic acid.

[0048] Preferably, the skin-penetrating essence is prepared using the following method:

[0049] Step 1: Mix the aqueous carrier, butanediol, propylene glycol, 1,2-hexanediol, and p-hydroxyacetophenone and heat to 70-80℃, stirring until completely dissolved to obtain an aqueous mixture.

[0050] Step 2: Mix ethanol, dimethyl sulfone, tranexamic acid, and arbutin, then add the pre-prepared azelaic acid-dimethyl sulfone eutectic complex and stir to dissolve at 30-40°C to obtain an alcohol phase mixture.

[0051] Step 3: Mix resveratrol, salicylic acid, ginseng extract, angelica extract, oat extract, teosinte extract, centella asiatica extract, aloe vera extract, golden chamomile extract and caramel color, homogenize to obtain active ingredient premix;

[0052] Step 4: Add the alcohol phase mixture obtained in Step 2 to the aqueous phase mixture obtained in Step 1 while stirring, cool to 40-45℃, then add the active premixed solution obtained in Step 3, continue stirring and adjust the pH to 4.0-5.5, and finally add water to the total volume to obtain the final product.

[0053] (III) Beneficial Effects

[0054] Compared with existing technologies, this invention provides a skin-transparent essence that balances pigmentation and repairs cells, possessing the following beneficial effects:

[0055] 1. Brightening and fading effect: The tranexamic acid, arbutin, azelaic acid and salicylic acid in the formula work together to help inhibit melanin production, accelerate keratin metabolism, improve uneven skin tone and dullness, and make the skin more radiant and clear.

[0056] 2. Soothing and Repairing Effects: Extracts from plants such as Centella Asiatica, Aloe Vera, and Chamomile, combined with Stephania tetrandra, help soothe skin discomfort, reduce inflammation, and strengthen the skin barrier, thus reducing the risk of sensitivity and redness.

[0057] 3. Hydrating and moisturizing effect: Based on moisturizing ingredients such as propylene glycol and butylene glycol, combined with ingredients such as oat extract, it helps the skin lock in moisture, relieves dryness and tightness, and keeps the skin in a supple and moisturized state. Detailed Implementation

[0058] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0059] To better understand the present invention, the technical solutions of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the present invention. All technical solutions implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0060] Unless otherwise specified, all raw materials used in the following examples are known products that can be directly purchased from the market. Specifically, the ginseng extract contains 0.5-2 wt% ginsenoside Rg1, the angelica extract contains 0.3-1.5 wt% ferulic acid, the Stephania tetrandra extract contains 5-15 wt% tetanine, and the Centella asiatica extract contains 10-25 wt% asiaticoside. The oat extract is an enzymatically hydrolyzed extract with a β-glucan content of not less than 20 wt%, and the aloe vera extract is an extract with an acetylated mannan content of not less than 15 wt%.

[0061] In the following examples, the azelaic acid-dimethyl sulfone eutectic complex was prepared in advance as follows: azelaic acid and dimethyl sulfone were mixed in a molar ratio of 1:0.8-1.2, placed in a reaction vessel, heated and stirred in a water bath at 40-50°C until completely melted to form a homogeneous liquid, and then naturally cooled to room temperature. After solidification, it was ground into a fine powder and passed through a 100-mesh sieve to obtain the final product.

[0062] Example 1

[0063] Based on the total weight of the transdermal essence as 100%, the components and their contents are as follows: aqueous carrier (water) to 100%, ethanol 2.0%, propylene glycol 3.0%, tranexamic acid 1.0%, resveratrol 0.5%, salicylic acid 0.2%, arbutin 1.0%, dimethyl sulfone 0.5%, butylene glycol 2.0%, azelaic acid 0.5%, ginseng extract 0.1%, angelica extract 0.1%, oat extract 0.5%, Stephania tetrandra extract 0.2%, centella asiatica extract 0.5%, aloe vera extract 0.5%, golden chamomile extract 0.2%, caramel color 0.01%, 1,2-hexanediol 0.5%, p-hydroxyacetophenone 0.1%.

[0064] The mass ratio of tranexamic acid, arbutin, and azelaic acid is 1:1:0.5, and the mass ratio of resveratrol to salicylic acid is 1:0.4. Azelaic acid and dimethyl sulfone are added in the form of a pre-prepared eutectic complex at a molar ratio of 1:0.8. The mass ratio of Stephania tetrandra extract to Centella asiatica extract is 1:2.5. The mass ratio of ethanol, propylene glycol, and butylene glycol is 1:1.5:1.

[0065] The preparation method of the transdermal serum in this embodiment includes the following steps:

[0066] Step 1: Mix water, butanediol, propylene glycol, 1,2-hexanediol, and p-hydroxyacetophenone as the aqueous phase carrier and heat to 75°C. Stir at 300 rpm until completely dissolved to obtain an aqueous phase mixture.

[0067] Step 2: Mix ethanol, dimethyl sulfone, tranexamic acid, and arbutin, then add the pre-prepared azelaic acid-dimethyl sulfone eutectic complex. Stir at 200 rpm at 35°C until completely dissolved to obtain an alcohol phase mixture.

[0068] Step 3: Mix resveratrol, salicylic acid, ginseng extract, angelica extract, oat extract, teosinte extract, centella asiatica extract, aloe vera extract, golden chamomile extract and caramel color, and homogenize using a high-shear homogenizer at 8000 rpm for 5 minutes to obtain an active ingredient premix.

[0069] Step 4: Slowly add the alcohol phase mixture obtained in Step 2 to the aqueous phase mixture obtained in Step 1 while stirring. Cool to 42°C, then add the active ingredient premix obtained in Step 3, and continue stirring for 15 minutes. Adjust the pH to 4.5 with citric acid or triethanolamine, and finally add water to the total volume to obtain the transdermal essence. It was determined that in this example, 72% of the salicylic acid existed in an undissociated molecular state.

[0070] Example 2

[0071] Based on the total weight of the transdermal essence as 100%, the components and their contents are as follows: aqueous carrier (water) to 100%, ethanol 4.0%, propylene glycol 5.0%, tranexamic acid 2.0%, resveratrol 1.0%, salicylic acid 0.5%, arbutin 2.0%, dimethyl sulfone 1.5%, butylene glycol 3.0%, azelaic acid 1.0%, ginseng extract 0.5%, angelica extract 0.5%, oat extract 1.0%, Stephania tetrandra extract 0.5%, centella asiatica extract 1.0%, aloe vera extract 1.0%, golden chamomile extract 0.5%, caramel color 0.03%, 1,2-hexanediol 1.0%, p-hydroxyacetophenone 0.3%.

[0072] The mass ratio of tranexamic acid, arbutin, and azelaic acid is 2:2:1, and the mass ratio of resveratrol to salicylic acid is 2:1. Azelaic acid and dimethyl sulfone are added in the form of a pre-prepared eutectic complex at a molar ratio of 1:1.0. The mass ratio of Stephania tetrandra extract to Centella asiatica extract is 1:2.0. The mass ratio of ethanol, propylene glycol, and butylene glycol is 1.3:1.7:1.

[0073] The preparation method in this embodiment is the same as in Example 1, except that the heating temperature in step one is 78°C, the dissolution temperature in step two is 38°C, the homogenization speed in step three is 10,000 rpm for 4 minutes, and the pH is adjusted to 5.0 in step four. It was determined that 78% of the salicylic acid in this embodiment exists in an undissociated molecular state.

[0074] Example 3

[0075] Based on the total weight of the transdermal essence as 100%, the components and their contents are as follows: aqueous carrier (water) to 100%, ethanol 5.0%, propylene glycol 6.0%, tranexamic acid 3.0%, resveratrol 1.5%, salicylic acid 1.0%, arbutin 2.5%, dimethyl sulfone 2.5%, butylene glycol 4.0%, azelaic acid 1.5%, ginseng extract 1.0%, angelica extract 1.0%, oat extract 2.0%, Stephania tetrandra extract 0.8%, Centella asiatica extract 1.6%, aloe vera extract 1.5%, golden chamomile extract 1.0%, caramel color 0.05%, 1,2-hexanediol 1.2%, p-hydroxyacetophenone 0.5%.

[0076] The mass ratio of tranexamic acid, arbutin, and azelaic acid is 3:2.5:1.5, and the mass ratio of resveratrol to salicylic acid is 1.5:1. Azelaic acid and dimethyl sulfone are added in the form of a pre-prepared eutectic complex at a molar ratio of 1:1.1. The mass ratio of Stephania tetrandra extract to Centella asiatica extract is 1:2.0. The mass ratio of ethanol, propylene glycol, and butylene glycol is 1.25:1.5:1.

[0077] The preparation method in this embodiment is the same as in Example 1, except that the heating temperature in step one is 80℃, the dissolution temperature in step two is 40℃, the homogenization speed in step three is 12000 rpm for 3 minutes, and the pH is adjusted to 4.8 in step four. It was determined that 75% of the salicylic acid in this embodiment exists in an undissociated molecular state.

[0078] Example 4

[0079] Based on the total weight of the transdermal essence as 100%, the components and their contents are as follows: aqueous carrier (water) to 100%, ethanol 6.0%, propylene glycol 8.0%, tranexamic acid 4.0%, resveratrol 2.0%, salicylic acid 1.5%, arbutin 3.0%, dimethyl sulfone 3.0%, butylene glycol 4.1%, azelaic acid 2.0%, ginseng extract 1.5%, angelica extract 1.5%, oat extract 2.5%, Stephania tetrandra extract 1.2%, Centella asiatica extract 2.4%, aloe vera extract 2.0%, golden chamomile extract 1.5%, caramel color 0.08%, 1,2-hexanediol 1.5%, p-hydroxyacetophenone 0.8%.

[0080] The mass ratio of tranexamic acid, arbutin, and azelaic acid is 4:3:2, and the mass ratio of resveratrol to salicylic acid is 1.33:1. Azelaic acid and dimethyl sulfone are added in the form of a pre-prepared eutectic complex at a molar ratio of 1:0.9. The mass ratio of Stephania tetrandra extract to Centella asiatica extract is 1:2.0. The mass ratio of ethanol, propylene glycol, and butylene glycol is 1.2:1.6:1.

[0081] The preparation method in this embodiment is the same as in Example 1, except that the heating temperature in step one is 72℃, the dissolution temperature in step two is 32℃, the homogenization speed in step three is 9000 rpm for 6 minutes, and the pH is adjusted to 4.2 in step four. It was determined that in this embodiment, 68% of the salicylic acid exists in an undissociated molecular state.

[0082] Example 5

[0083] Based on the total weight of the transdermal essence as 100%, the components and their contents are as follows: aqueous carrier (water) to 78.24%, ethanol 8.0%, propylene glycol 10.0%, tranexamic acid 5.0%, resveratrol 3.0%, salicylic acid 2.0%, arbutin 4.0%, dimethyl sulfone 4.0%, butylene glycol 6.0%, azelaic acid 3.0%, ginseng extract 2.0%, angelica extract 2.0%, oat extract 3.0%, Stephania tetrandra extract 1.5%, Centella asiatica extract 3.0%, aloe vera extract 2.5%, golden chamomile extract 2.0%, caramel color 0.10%, 1,2-hexanediol 2.0%, p-hydroxyacetophenone 1.0%.

[0084] The mass ratio of tranexamic acid, arbutin, and azelaic acid is 5:4:3, and the mass ratio of resveratrol to salicylic acid is 1.5:1. Azelaic acid and dimethyl sulfone are added in the form of a pre-prepared eutectic complex at a molar ratio of 1:1.2. The mass ratio of Stephania tetrandra extract to Centella asiatica extract is 1:2.0. The mass ratio of ethanol, propylene glycol, and butylene glycol is 1.33:1.67:1.

[0085] The preparation method in this embodiment is the same as in Example 1, except that the heating temperature in step one is 70℃, the dissolution temperature in step two is 30℃, the homogenization speed in step three is 11000 rpm for 5 minutes, and the pH is adjusted to 5.5 in step four. It was determined that 82% of the salicylic acid in this embodiment exists in an undissociated molecular state.

[0086] In summary, the skin-balancing and cell-repairing essence provided by this invention, through a specific ratio of polyol penetration-enhancing system, azelaic acid-dimethyl sulfone eutectic complex, and a specific ratio of Stephania tetrandra and Centella asiatica extracts, supplemented with ginseng, angelica, and other plant extracts, exhibits excellent technical effects in terms of stability, transdermal absorption rate, pigment inhibition, cell repair, and skin whitening and spot-fading effects.

[0087] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A skin-penetrating essence that balances pigmentation and repairs cells, characterized in that, The skin-penetrating essence is composed of the following components by weight percentage: Aqueous carrier 45-80%; Ethanol 2-8%; Propylene glycol 3-10%; Tranexamic acid 1-5%; Resveratrol 0.5-3%; Salicylic acid 0.2-2%; Arbutin 1-4%; Dimethyl sulfone 0.5-4%; Butanediol 2-6%; Azelaic acid 0.5-3%; Ginseng extract 0.1-2%; Angelica sinensis extract 0.1-2%; Oat extract 0.5-3%; Stephania tetrandra extract 0.2-1.5%; Centella asiatica extract 0.5-3%; Curacao aloe vera extract 0.5-2.5%; Golden chamomile extract 0.2-2%; Caramel color 0.01-0.1%; 1,2-Hexanediol 0.5-2%; p-Hydroxyacetophenone 0.1-1%.

2. The skin-penetrating essence according to claim 1, characterized in that, The mass ratio of tranexamic acid, arbutin and azelaic acid is (1-3):(1-2):(0.5-1.5), and the mass ratio of resveratrol and salicylic acid is (1-2):(0.5-1). The azelaic acid and the dimethyl sulfone form a eutectic complex in a molar ratio of 1:0.8-1.

2. The eutectic complex is prepared by mixing azelaic acid and dimethyl sulfone, heating and stirring at 40-50°C until completely melted, then cooling to room temperature and grinding into powder.

3. The skin-penetrating essence according to claim 1, characterized in that, The mass ratio of the Stephania tetrandra extract to the Centella asiatica extract is 1:(1.5-3). The content of fangchi alkaloid in the powdered fangchi extract is 5-15 wt%, and the content of asiaticoside in the centella asiatica extract is 10-25 wt%.

4. The skin-penetrating essence according to claim 1, characterized in that, The transdermal essence also contains liposomes, which are composed of hydrogenated lecithin, cholesterol, resveratrol, ginseng extract, and angelica extract, in a mass ratio of (5-10):(1-2):(1-1.5):(0.5-1). The liposomes have a particle size of 80-150 nm, and the resveratrol, ginseng extract, and angelica extract are encapsulated together in the aqueous phase of the liposomes.

5. The skin-penetrating essence according to claim 1, characterized in that, The oat extract is an enzymatically hydrolyzed extract with a β-glucan content ≥20wt%, and the aloe vera extract is an extract with an acetylated mannan content ≥15wt%. The mass ratio of 1,2-hexanediol to p-hydroxyacetophenone is (1-2):(0.5-1). The caramel color has a color factor of 0.1-0.5 and a transmittance of ≤10% in the wavelength range of 290-320nm.

6. The skin-penetrating essence according to claim 1, characterized in that, The pH value of the transdermal essence is 4.0-5.5, and the mass ratio of ethanol, propylene glycol and butylene glycol is (1-2):(2-4):(1-3). At this mass ratio and pH value, the proportion of salicylic acid existing in an undissociated molecular state is 65-85%.

7. The skin-penetrating essence according to claim 1, characterized in that, The mass ratio of dimethyl sulfone, tranexamic acid and resveratrol is (1-2):(2-4):(1-2); The ginseng extract contains 0.5-2 wt% ginsenoside Rg1, and the angelica extract contains 0.3-1.5 wt% ferulic acid.

8. The skin-penetrating essence according to any one of claims 1-7, characterized in that, The skin-penetrating essence is prepared using the following method: Step 1: Mix the aqueous carrier, butanediol, propylene glycol, 1,2-hexanediol, and p-hydroxyacetophenone and heat to 70-80℃, stirring until completely dissolved to obtain an aqueous mixture. Step 2: Mix ethanol, dimethyl sulfone, tranexamic acid, and arbutin, then add the pre-prepared azelaic acid-dimethyl sulfone eutectic complex and stir to dissolve at 30-40°C to obtain an alcohol phase mixture. Step 3: Mix resveratrol, salicylic acid, ginseng extract, angelica extract, oat extract, teosinte extract, centella asiatica extract, aloe vera extract, golden chamomile extract and caramel color, homogenize to obtain active ingredient premix; Step 4: Add the alcohol phase mixture obtained in Step 2 to the aqueous phase mixture obtained in Step 1 while stirring, cool to 40-45℃, then add the active premixed solution obtained in Step 3, continue stirring and adjust the pH to 4.0-5.5, and finally add water to the total volume to obtain the final product.